Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지
DOI QR코드

DOI QR Code

Clinical outcomes after sentinel lymph node biopsy in clinically node-negative breast cancer patients

  • Han, Hee Ji (Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine) ;
  • Kim, Ju Ree (Department of Radiation Oncology, Cheil General Hospital) ;
  • Nam, Hee Rim (Department of Radiation Oncology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine) ;
  • Keum, Ki Chang (Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine) ;
  • Suh, Chang Ok (Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine) ;
  • Kim, Yong Bae (Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine)
  • Received : 2014.04.21
  • Accepted : 2014.07.01
  • Published : 2014.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: To evaluate non-sentinel lymph node (LN) status after sentinel lymph node biopsy (SNB) in patients with breast cancer and to identify the predictive factors for disease failure. Materials and Methods: From January 2006 to December 2007, axillary lymph node (ALN) dissection after SNB was performed for patients with primary invasive breast cancer who had no clinical evidence of LN metastasis. A total of 320 patients were treated with breast-conserving surgery and radiotherapy. Results: The median age of patients was 48 years, and the median follow-up time was 72.8 months. Close resection margin (RM) was observed in 13 patients. The median number of dissected SNB was two, and that of total retrieved ALNs was 11. Sentinel node accuracy was 94.7%, and the overall false negative rate (FNR) was 5.3%. Eleven patients experienced treatment failure. Local recurrence, regional LN recurrence, and distant metastasis were identified in 0.9%, 1.9%, and 2.8% of these patients, respectively. Sentinel LN status were not associated with locoregional recurrence (p > 0.05). Close RM was the only significant factor for disease-free survival (DFS) in univariate and multivariate analysis. The 5-year overall survival, DFS, and locoregional DFS were 100%, 96.8%, and 98.1%, respectively. Conclusion: In this study, SNB was performed with high accuracy and low FNR and high locoregional control was achieved.

Keywords

References

  1. Veronesi U, Paganelli G, Galimberti V, et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet 1997;349:1864-7. https://doi.org/10.1016/S0140-6736(97)01004-0
  2. Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymphnode resection compared with conventional axillary-lymphnode dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 2010;11:927-33. https://doi.org/10.1016/S1470-2045(10)70207-2
  3. Veronesi U, Viale G, Paganelli G, et al. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg 2010;251:595-600. https://doi.org/10.1097/SLA.0b013e3181c0e92a
  4. Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst 2006;98:599-609. https://doi.org/10.1093/jnci/djj158
  5. Straver ME, Meijnen P, van Tienhoven G, et al. Role of axillary clearance after a tumor-positive sentinel node in the administration of adjuvant therapy in early breast cancer. J Clin Oncol 2010;28:731-7. https://doi.org/10.1200/JCO.2008.21.7554
  6. Grube BJ, Giuliano AE. Observation of the breast cancer patient with a tumor-positive sentinel node: implications of the ACOSOG Z0011 trial. Semin Surg Oncol 2001;20:230-7. https://doi.org/10.1002/ssu.1038
  7. Galimberti V, Cole BF, Zurrida S, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol 2013;14:297-305. https://doi.org/10.1016/S1470-2045(13)70035-4
  8. Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 2011;305:569-75. https://doi.org/10.1001/jama.2011.90
  9. Giuliano AE, McCall L, Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg 2010;252:426-33.
  10. Donker M, Straver ME, van Tienhoven G, et al. Comparison of the sentinel node procedure between patients with multifocal and unifocal breast cancer in the EORTC 10981-22023 AMAROS Trial: identification rate and nodal outcome. Eur J Cancer 2013;49:2093-100. https://doi.org/10.1016/j.ejca.2013.02.017
  11. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994;220:391-401. https://doi.org/10.1097/00000658-199409000-00015
  12. Veronesi U, Galimberti V, Paganelli G, et al. Axillary metastases in breast cancer patients with negative sentinel nodes: a follow-up of 3548 cases. Eur J Cancer 2009;45:1381-8. https://doi.org/10.1016/j.ejca.2008.11.041
  13. Bilimoria KY, Bentrem DJ, Hansen NM, et al. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol 2009;27:2946-53. https://doi.org/10.1200/JCO.2008.19.5750
  14. Naik AM, Fey J, Gemignani M, et al. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection: a follow-up study of 4008 procedures. Ann Surg 2004;240:462-71. https://doi.org/10.1097/01.sla.0000137130.23530.19
  15. van der Ploeg IM, Nieweg OE, van Rijk MC, Valdes Olmos RA, Kroon BB. Axillary recurrence after a tumour-negative sentinel node biopsy in breast cancer patients: a systematic review and meta-analysis of the literature. Eur J Surg Oncol 2008;34:1277-84. https://doi.org/10.1016/j.ejso.2008.01.034
  16. Goodwin P. For patients with sentinel node-positive early breast cancer, RT as effective as and less toxic than complete surgical axillary clearance. Oncol Times 2013;35:33-4.
  17. Miltenburg DM, Miller C, Karamlou TB, Brunicardi FC. Metaanalysis of sentinel lymph node biopsy in breast cancer. J Surg Res 1999;84:138-42. https://doi.org/10.1006/jsre.1999.5629
  18. Ban EJ, Lee JS, Koo JS, Park S, Kim SI, Park BW. How many sentinel lymph nodes are enough for accurate axillary staging in T1-2 breast cancer? J Breast Cancer 2011;14:296-300. https://doi.org/10.4048/jbc.2011.14.4.296

Cited by

  1. Simple Prediction Model of Axillary Lymph Node Positivity After Analyzing Molecular and Clinical Factors in Early Breast Cancer vol.95, pp.20, 2016, https://doi.org/10.1097/md.0000000000003689
  2. Complications and outcomes following inguinal lymphadenectomy for malignant melanoma in an Asian population vol.16, pp.2, 2014, https://doi.org/10.14216/kjco.20012